You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

A Practitioner’s Guide to Hepatobiliary Carcinoma: Immunotherapy Edition

  • Authors: Richard S. Finn, MD; Laura M. Kulik, MD; Josep M. Llovet, MD, PhD, FAASLD
  • CME / ABIM MOC Released: 6/24/2022
  • Valid for credit through: 6/24/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for gastroenterologists, oncologists, and other clinicians involved in the care of patients at risk of or diagnosed with hepatobiliary cancers.

The goal of this activity is to improve clinicians’ knowledge and confidence in managing patients with hepatobiliary carcinomas.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding
    • Patients who are at risk of developing hepatobiliary carcinoma
    • Management of patients at risk of developing hepatobiliary carcinoma
    • Immunotherapy approaches in the management of patients with hepatobiliary carcinoma
    • Immunotherapy approaches in the management of patients with hepatobiliary carcinoma
    • The role of the multidisciplinary team (MDT) in the management of patients receiving immunotherapy-based treatments for hepatobiliary carcinoma
  • Demonstrate greater confidence in their ability to
    • Communicate effectively with the MDT regarding the care of patients with hepatobiliary carcinoma


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Richard S. Finn, MD

    Professor of Medicine, Division of Hematology/Oncology
    Geffen School of Medicine at UCLA
    Jonsson Comprehensive Cancer Center
    Los Angeles, California

    Disclosures

    Richard S. Finn, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Adaptimmune; AstraZeneca; Bayer; BMS, CStone; Eisai, EliLilly; Hengrui; Merck; Pfizer; Roche/ Genentech
    Research funding from: Adaptimmune; Bayer; BMS; Eisai; Eli Lilly; Merck; Pfizer; Roche/Genentech

  • Laura M. Kulik, MD

    Professor of Medicine
    Interventional Radiology and Transplant Surgery
    Feinberg School of Medicine
    Northwestern University
    Chicago, Illinois

    Disclosures

    Laura M. Kulik, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Bayer; Eisai; Exelixis; Genetec; Gilead; Merck
    Speaker or member of speakers bureau for: Eisai; Gilead; Roche
    Research funding from: Glycotest; HCC Target

  • Josep M. Llovet, MD, PhD, FAASLD

    Professor of Medicine
    Director, Mount Sinai Liver Cancer Program
    Division of Liver Diseases
    Tisch Cancer Institute
    Icahn School of Medicine at Mount Sinai
    New York, New York

    Disclosures

    Josep M. Llovet, MD, PhD, FAASLD , has the following relevant financial relationships: 
    Consultant or advisor for: AstraZeneca; Bayer; Boston Scientific; Bristol Myers Squibb Company; Eisai; Eli Lilly; Genentech; Glycotest; Ipsen; Iylon; Merck; Mina Alpha; Nucleix; Omega
    Research funding from: Bayer; Boehringer Ingelheim; Eisai; Ipsen
     

Editors

  • John Churchwell, PhD

    Medical Education Director, Medscape, LLC

    Disclosures

    John Churchwell, PhD, has the following relevant financial relationships: he was employed by Medtronic (ended 2021)

  • Davecia Ragoonath Cameron, MS

    Medical Education Director,Medscape, LLC

    Disclosures

    Davecia Ragoonath Cameron, MS, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

A Practitioner’s Guide to Hepatobiliary Carcinoma: Immunotherapy Edition

Authors: Richard S. Finn, MD; Laura M. Kulik, MD; Josep M. Llovet, MD, PhD, FAASLDFaculty and Disclosures

CME / ABIM MOC Released: 6/24/2022

Valid for credit through: 6/24/2023

processing....

Educational Impact Challenge

The goal of this activity is to improve clinicians’ knowledge and confidence in managing patients with hepatobiliary carcinomas.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print